Eledon Pharmaceuticals (Nasdaq:ELDN) - Prezzo delle azioni, notizie e analisi

ELDN Panoramica delle azioni

Eledon Pharmaceuticals, Inc. opera come società di biotecnologie in fase clinica.

ELDN analisi fondamentale
Punteggio fiocco di neve
Valutazione	0/6
Crescita futura	2/6
Prestazioni passate	0/6
Salute finanziaria	3/6
Dividendi	0/6

Premi

Si prevede che i ricavi cresceranno 39.23% all'anno

Analisi del rischio

Realizza un fatturato inferiore a 1 milione di dollari ( $0 )

Patrimonio netto negativo

Gli azionisti sono stati sostanzialmente diluiti nell'ultimo anno

Attualmente non redditizio e non si prevede che diventerà redditizio nei prossimi 3 anni

Eledon Pharmaceuticals, Inc. Concorrenti

Vigil Neuroscience

NasdaqGS:VIGL

US$149.9m

Generation Bio

NasdaqGS:GBIO

US$145.5m

Leap Therapeutics

NasdaqCM:LPTX

US$143.1m

Yumanity Therapeutics

NasdaqCM:YMTX

US$143.6m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Eledon Pharmaceuticals
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$4.65
Massimo di 52 settimane	US$4.76
Minimo di 52 settimane	US$1.07
Beta	0.88
1Variazione di 1 mese	85.26%
Variazione a 3 mesi	68.48%
Variazione di 1 anno	278.05%
3Variazione a 3 anni	-6.44%
Variazione a 5 anni	-61.82%
Variazione dall'IPO	-95.95%

Notizie e aggiornamenti recenti

Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart

Oct 29

Recent updates

Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart

Oct 29

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Mar 22

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Dec 05

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Aug 10

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Apr 27

Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation

Jan 05

Eledon begins dosing in early-stage study of tegoprubart in kidney transplant patients

Jul 18

Eledon gives update on development strategy for AT-1501 in renal transplantation

Apr 26

Eledon Pharmaceuticals (NASDAQ:ELDN) Is In A Good Position To Deliver On Growth Plans

Apr 14

What Type Of Shareholders Make Up Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) Share Registry?

Feb 21

Here's Why We're Not Too Worried About Novus Therapeutics' (NASDAQ:NVUS) Cash Burn Situation

Dec 30

Novus Therapeutics (NVUS) Investor Presentation - Slideshow

Dec 18

Novus Therapeutics EPS misses by $3.76

Nov 16

Enrollment underway in Novus Therapeutics' mid-stage AT-1501 trial in neuromuscular disease

Nov 02

Rendimenti per gli azionisti

	ELDN	US Biotechs	US Mercato
7D	37.2%	0.5%	0.5%
1Y	278.0%	24.7%	36.8%

Ritorno vs Industria: ELDN ha superato il US Biotechs che ha restituito 24.7 % nell'ultimo anno.

Rendimento vs Mercato: ELDN ha superato il mercato US che ha restituito 36.8 % nell'ultimo anno.

Volatilità dei prezzi

Is ELDN's price volatile compared to industry and market?
ELDN volatility
ELDN Average Weekly Movement	8.9%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.1%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.0%

Prezzo delle azioni stabile: ELDN non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 9% ) di ELDN è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
n/a	20	DA Gros	eledon.com

Eledon Pharmaceuticals, Inc. opera come società di biotecnologie in fase clinica. L'azienda sfrutta la sua esperienza immunologica nel colpire la via del ligando CD40 (CD40L, detto anche CD154) per sviluppare terapie volte a proteggere gli organi trapiantati e a prevenire il rigetto, nonché a trattare la sclerosi laterale amiotrofica (SLA). Il composto principale dell'azienda in fase di sviluppo è tegoprubart, un anticorpo IgG1 e anti-CD40L con elevata affinità per il ligando CD40, un bersaglio biologico con potenziale terapeutico.

Eledon Pharmaceuticals, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Eledon Pharmaceuticals con la sua capitalizzazione di mercato?
ELDN statistiche fondamentali
Capitalizzazione di mercato	US$277.79m
Guadagni(TTM)	-US$108.54m
Ricavi(TTM)	n/a

0.0x

Rapporto P/S

-2.6x

Rapporto P/E

ELDN è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
ELDN Conto economico (TTM)
Ricavi	US$0
Costo del fatturato	US$0
Profitto lordo	US$0
Altre spese	US$108.54m
Guadagni	-US$108.54m

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-1.82
Margine lordo	0.00%
Margine di profitto netto	0.00%
Rapporto debito/patrimonio netto	0%

Come si è comportato ELDN nel lungo periodo?

Vedi performance storica e confronto

ELDN Panoramica delle azioni

Premi

Analisi del rischio

Eledon Pharmaceuticals, Inc. Concorrenti

NasdaqGS:VIGL

US$149.9m

NasdaqGS:GBIO

US$145.5m

NasdaqCM:LPTX

US$143.1m

NasdaqCM:YMTX

US$143.6m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Eledon Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $84.9951 million.

Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart

Eledon Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Eledon Pharmaceuticals, Inc. announced delayed 10-Q filing

Eledon Pharmaceuticals, Inc. Provides Enrollment Update for Phase 2 Bestow Trial Assessing Tegoprubart for the Prevention of Organ Rejection

Eledon Pharmaceuticals, Inc. Presents Updated Data from Ongoing Phase 1B Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Recent updates

Eledon Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $84.9951 million.

Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart

Eledon Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Eledon Pharmaceuticals, Inc. announced delayed 10-Q filing

Eledon Pharmaceuticals, Inc. Provides Enrollment Update for Phase 2 Bestow Trial Assessing Tegoprubart for the Prevention of Organ Rejection

Eledon Pharmaceuticals, Inc. Presents Updated Data from Ongoing Phase 1B Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Eledon Pharmaceuticals, Inc., Annual General Meeting, Jul 10, 2024

New major risk - Shareholder dilution

Price target decreased by 10% to US$14.00

Eledon Pharmaceuticals, Inc. announced that it expects to receive $49.99901 million in funding

New minor risk - Share price stability

Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Eledon Pharmaceuticals, Inc. Reports Updated Data from Ongoing Phase 1B Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Eledon Pharmaceuticals, Inc. Appoints of Eliezer Katz as Chief Medical Officer

Insufficient new directors

Eledon Pharmaceuticals Appoints Allan Douglas Kirk to Board of Directors

Price target decreased by 10% to US$16.50

Eledon Pharmaceuticals, Inc. Appoints James Robinson to Its Board of Directors, Effective October 1, 2023

Eledon Pharmaceuticals, Inc. Announces First Participant Dosed in Phase 2 Bestow Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation

Eledon Pharmaceuticals, Inc. Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

New major risk - Financial position

Eledon Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 11, 2023

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Price target decreased to US$19.40

Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation

Eledon Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Eledon Pharmaceuticals, Inc. Receives FDA Clearance of IND Application to Evaluate Tegoprubart in IgA Nephropathy

Eledon adds 10% as FDA clears clinical trial for kidney disease candidate

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Invest In Growth?

Eledon Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart for the Prevention of Rejection in Kidney Transplant Recipients

Eledon gets FDA nod to start trial of organ rejection preventing therapy

Eledon Pharmaceuticals Announces the First Patient Dosed in Phase 1B Trial Evaluating Tegoprubart in Kidney Transplantation

Eledon begins dosing in early-stage study of tegoprubart in kidney transplant patients

Eledon Announces Positive Topline Results from Phase 2a Trial of Tegoprubart Demonstrating Safety, Target Engagement, and Biomarker Response in Patients Living with Amyotrophic Lateral Sclerosis

Eledon Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2a Trial Evaluating Tegoprubart in IgA Nephropathy

Eledon Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 12, 2022

Price target decreased to US$28.80

Price target decreased to US$29.75

Senior VP of Administration & Principal Accounting Officer Jon Kuwahara has left the company

Chief Financial Officer recently bought US$89k worth of stock

Eledon Pharmaceuticals, Inc. Announces Update on Development Strategy for AT-1501 in Renal Transplantation

Eledon gives update on development strategy for AT-1501 in renal transplantation

Eledon Pharmaceuticals (NASDAQ:ELDN) Is In A Good Position To Deliver On Growth Plans

Eledon Pharmaceuticals, Inc. Announces Appointments of Paul Little as Chief Financial Officer

New 90-day low: US$12.66

What Type Of Shareholders Make Up Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) Share Registry?

Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from NASDAQ Composite Index

Here's Why We're Not Too Worried About Novus Therapeutics' (NASDAQ:NVUS) Cash Burn Situation

New 90-day low: US$14.76

Price target raised to US$35.00

Novus Therapeutics (NVUS) Investor Presentation - Slideshow

Novus Therapeutics, Inc. Appoints June Lee to the Board of Directors

Novus Therapeutics EPS misses by $3.76

Novus Therapeutics, Inc. to Report Q3, 2020 Results on Nov 16, 2020

Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis